International Immunology Advance Access originally published online on October 5, 2004
International Immunology 2004 16(11):1633-1641; doi:10.1093/intimm/dxh166
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 The Japanese Society for Immunology
The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-ß2Glycoprotein I antibodies
Department of Medicine II, Hokkaido University Graduate School of Medicine, N-15 W-7, Kita-ku, Sapporo 060-8648, Japan
Correspondence to: T. Atsumi; E-mail: at3tat{at}med.hokudai.ac.jp
The anti-phospholipid syndrome (APS) is characterized by thrombosis and the presence of anti-phospholipid antibodies (aPL). Tissue factor (TF), the major initiator of the coagulation system, is induced on monocytes by aPL in vitro, explaining, in part, the pathophysiology in this syndrome. However, little is known regarding the nature of the aPL-induced signal transduction pathways leading to TF expression. In this study, we investigated aPL-inducible genes in PBMC using cDNA array system and real-time PCR. Our results indicated that the mitogen-activated protein kinase (MAPK) pathway was related to TF expression when PBMCs were treated, in the presence of ß2Glycoprotein I (ß2GPI), with human monoclonal anti-ß2GPI antibodies [ß2GPI-dependent anti-cardiolipin antibodies (aCL/ß2GPI)]. Western blotting studies using monocyte cell line (RAW264.7) demonstrated that p38 MAPK protein was phosphorylated with nuclear factor 
B (NF-B) activation by monoclonal aCL/ß2GPI treatment, and that SB203580, a specific p38 MAPK inhibitor, decreased the aCL/ß2GPI-induced TF mRNA expression. The p38 MAPK phosphorylation, NF-B translocation and TF mRNA expression triggered by aCL/ß2GPI were abolished in the absence of ß2GPI. These results demonstrated that the p38 MAPK signaling pathway plays an important role in aPL-induced TF expression on monocytes and suggest that the p38 MAPK may be a possible therapeutic target to modify a pro-thrombotic state in patients with APS.
Keywords: anti-cardiolipin antibody, anti-phospholipid antibody, anti-phospholipid syndrome, thrombosis
Transmitting editor: K. Okumura
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K Oku, T Atsumi, M Bohgaki, O Amengual, H Kataoka, T Horita, S Yasuda, and T Koike Complement activation in patients with primary antiphospholipid syndrome Ann Rheum Dis, June 1, 2009; 68(6): 1030 - 1035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Lopez-Pedrera, N Barbarroja, M. Aguirre, L. Torres, F Velasco, and M. Cuadrado Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases Lupus, October 1, 2008; 17(10): 905 - 916. [Abstract] [PDF]
|
|
|
|
|
|
A. Kinev and R. Roubey Tissue factor in the antiphospholipid syndrome Lupus, October 1, 2008; 17(10): 953 - 959. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Atsumi New therapeutic targets for antiphospholipid syndrome Blood, December 15, 2007; 110(13): 4141 - 4141. [Full Text] [PDF]
|
|
|
|
|
|
C Hamid, K Norgate, D P D'Cruz, M A Khamashta, M Arno, J D Pearson, G Frampton, and J J Murphy Anti-{beta}2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome Ann Rheum Dis, August 1, 2007; 66(8): 1000 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Giannakopoulos, F. Passam, S. Rahgozar, and S. A. Krilis Current concepts on the pathogenesis of the antiphospholipid syndrome Blood, January 15, 2007; 109(2): 422 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lopez-Pedrera, P Buendia, M A Aguirre, F Velasco, and M J Cuadrado Antiphospholipid syndrome and tissue factor: a thrombotic couple Lupus, March 1, 2006; 15(3): 161 - 166. [Abstract] [PDF]
|
|
|
|
|
|
T Koike and T Atsumi Antiphospholipid antibodies and cell activation: crucial role of p38 MAPK pathway Lupus, October 1, 2005; 14(10): 799 - 801. [PDF]
|
|